Rescriptor is a drug owned by Viiv Healthcare Co. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 07, 2019. Details of Rescriptor's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6177101 | Delavirdine high strength tablet formulation |
Jun, 2019
(5 years ago) |
Expired
|
| US5563142 | Diaromatic substituted compounds as anti-HIV-1 agents |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Rescriptor is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rescriptor's family patents as well as insights into ongoing legal events on those patents.
Rescriptor's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Rescriptor's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 07, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Rescriptor Generics:
There are no approved generic versions for Rescriptor as of now.
About Rescriptor
Rescriptor is a drug owned by Viiv Healthcare Co. Rescriptor uses Delavirdine Mesylate as an active ingredient. Rescriptor was launched by Viiv Hlthcare in 1997.
Approval Date:
Rescriptor was approved by FDA for market use on 04 April, 1997.
Active Ingredient:
Rescriptor uses Delavirdine Mesylate as the active ingredient. Check out other Drugs and Companies using Delavirdine Mesylate ingredient
Dosage:
Rescriptor is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Discontinued | ORAL |
| 100MG | TABLET | Discontinued | ORAL |